IS2909B - Sértækt sykursteraefnasamband sem hefur bólgueyðandi virkni - Google Patents

Sértækt sykursteraefnasamband sem hefur bólgueyðandi virkni

Info

Publication number: IS2909B
Authority: IS; Iceland
Prior art keywords: inflammatory activity; glucocorticoid compound; specific glucocorticoid; compound; specific
Prior art date: 2003-07-11

Application number

IS8193A

Other languages

English (en)

Other versions

IS8193A (is

Inventor

Keith Biggadike

Matthew Peter John

Deborah Needham

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-11

Filing date

2005-12-22

Publication date

2014-11-15

2005-12-22 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2005-12-22 Publication of IS8193A publication Critical patent/IS8193A/is

2014-11-15 Publication of IS2909B publication Critical patent/IS2909B/is

Links

230000003110 anti-inflammatory effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003862 glucocorticoid Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS8193A 2003-07-11 2005-12-22 Sértækt sykursteraefnasamband sem hefur bólgueyðandi virkni IS2909B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0316290.6A GB0316290D0 (en)	2003-07-11	2003-07-11	Novel compounds
PCT/EP2004/007819 WO2005005451A1 (en)	2003-07-11	2004-07-09	Specific glucocorticosteroid compound having anti- inflammatory activity

Publications (2)

Publication Number	Publication Date
IS8193A IS8193A (is)	2005-12-22
IS2909B true IS2909B (is)	2014-11-15

Family

ID=27742019

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IS8194A IS2776B (is)	2003-07-11	2005-12-22	Sértækt sykurstera efnasamband sem hefur bólgueyðandi virkni
IS8193A IS2909B (is)	2003-07-11	2005-12-22	Sértækt sykursteraefnasamband sem hefur bólgueyðandi virkni
IS050094A IS2928B (is)	2003-07-11	2014-10-28	Aðferð til að útbúa sykursteraefnasambönd

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IS8194A IS2776B (is)	2003-07-11	2005-12-22	Sértækt sykurstera efnasamband sem hefur bólgueyðandi virkni

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IS050094A IS2928B (is)	2003-07-11	2014-10-28	Aðferð til að útbúa sykursteraefnasambönd

Country Status (30)

Country	Link
US (6)	US7291609B2 (is)
EP (3)	EP1644397B1 (is)
JP (3)	JP4709752B2 (is)
KR (2)	KR101075324B1 (is)
CN (3)	CN102372756A (is)
AR (2)	AR045901A1 (is)
AT (1)	ATE467638T1 (is)
AU (2)	AU2004255855B2 (is)
BR (2)	BRPI0412526A (is)
CA (2)	CA2531911C (is)
CY (2)	CY1110149T1 (is)
DE (1)	DE602004027137D1 (is)
DK (2)	DK1644397T3 (is)
ES (3)	ES2400821T3 (is)
GB (1)	GB0316290D0 (is)
HR (2)	HRP20100359T1 (is)
IL (3)	IL172776A (is)
IS (3)	IS2776B (is)
MA (2)	MA27897A1 (is)
MX (2)	MXPA06000442A (is)
MY (2)	MY137944A (is)
NO (2)	NO332041B1 (is)
NZ (2)	NZ544577A (is)
PL (2)	PL1644397T3 (is)
PT (2)	PT1644397E (is)
RU (3)	RU2348645C2 (is)
SI (2)	SI1644398T1 (is)
TW (2)	TWI338694B (is)
WO (2)	WO2005005452A1 (is)
ZA (2)	ZA200600223B (is)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0125259D0 (en) *	2001-10-20	2001-12-12	Glaxo Group Ltd	Novel compounds
GB2389530B (en)	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
GB0316290D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
DE102004025985A1 (de) *	2004-05-21	2005-12-15	Schering Ag	Estriol- und Estetrol-Prodrugs
DE102004025966A1 (de) *	2004-05-21	2005-12-15	Schering Ag	Estradiol-Prodrugs
EP1841780B1 (en)	2005-01-10	2011-07-27	Glaxo Group Limited	Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en) *	2005-01-10	2009-05-14	Glaxo Group Limited	Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
EP2484382A1 (en) *	2005-03-30	2012-08-08	Schering Corporation	Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
ATE552032T1 (de)	2005-07-14	2012-04-15	Lithera Inc	Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
AR060536A1 (es)	2006-04-20	2008-06-25	Glaxo Group Ltd	Agonista del receptor de glucocorticoides y composiciones farmaceuticas
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
GB0615108D0 (en) *	2006-07-28	2006-09-06	Glaxo Group Ltd	Novel formulations
ES2398480T3 (es) *	2006-10-17	2013-03-19	Lithera, Inc.	Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EA019819B1 (ru)	2008-05-23	2014-06-30	ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
WO2009147187A1 (en)	2008-06-05	2009-12-10	Glaxo Group Limited	4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010071865A1 (en)	2008-12-19	2010-06-24	Nuon Therapeutics, Inc.	Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) *	2008-12-19	2010-06-24	Nuon Therapeutics, Inc.	Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010102958A1 (en)	2009-03-09	2010-09-16	Glaxo Group Limited	4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
US8354539B2 (en)	2009-03-10	2013-01-15	Glaxo Group Limited	Indole derivatives as IKK2 inhibitors
JP2012520845A (ja)	2009-03-17	2012-09-10	グラクソグループリミテッド	Ｉｔｋ阻害剤として使用されるピリミジン誘導体
JP2012520684A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012520683A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120029054A1 (en)	2009-03-19	2012-02-02	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2408458A1 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en)	2009-03-27	2012-01-05	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2010229847A1 (en)	2009-03-27	2011-10-13	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
WO2010111471A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111490A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012524754A (ja)	2009-04-24	2012-10-18	グラクソグループリミテッド	Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
UY32571A (es)	2009-04-24	2010-11-30	Glaxo Group Ltd	Compuestos derivados de pirazol amida
TWI466884B (zh)	2009-04-30	2015-01-01	Glaxo Group Ltd	6-(1h-吲哚-4-基)-4-(5-{[4-(1-甲基乙基)-1-哌嗪基]甲基}-1,3-噁唑-2-基)-1h-吲唑、其醫藥組合物及作為激酶活性抑制劑之用途
US9132084B2 (en)	2009-05-27	2015-09-15	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
JP2012528140A (ja)	2009-05-29	2012-11-12	ファイザー・リミテッド	新規なグルココルチコイド受容体アゴニスト
WO2011032175A1 (en)	2009-09-14	2011-03-17	Nuon Therapeutics, Inc.	Combination formulations of tranilast and allopurinol and methods related thereto
WO2011067366A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Novel compounds
JP2013512879A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
KR20120113267A (ko) *	2010-01-15	2012-10-12	리쎄라 인코오포레이티드	동결건조 케이크 제제
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
ES2602972T3 (es)	2010-09-08	2017-02-23	Glaxosmithkline Intellectual Property Development Limited	Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
RS54286B1 (sr)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
WO2012052459A1 (en)	2010-10-21	2012-04-26	Glaxo Group Limited	Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2630126B1 (en)	2010-10-21	2015-01-07	Glaxo Group Limited	Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
CN103269693A (zh)	2010-11-24	2013-08-28	利赛拉公司	选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法
JP5959541B2 (ja)	2011-02-25	2016-08-02	ノバルティスアーゲー	Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
US20140005188A1 (en)	2011-03-11	2014-01-02	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US10155001B2 (en)	2013-06-14	2018-12-18	Inserm (Institut National De La Sante Et De La Recherche Medicale)	RAC1 inhibitors for inducing bronchodilation
WO2015055691A1 (en)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Pi3k inhibitor for treatment of respiratory disease
AU2014336250A1 (en)	2013-10-17	2016-04-14	Glaxosmithkline Intellectual Property Development Limited	PI3K inhibitor for treatment of respiratory disease
KR20170003673A (ko)	2014-05-12	2017-01-09	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	감염성 질환을 치료하기 위한 다니릭신을 포함하는 약제 조성물
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
US20190161480A1 (en)	2016-08-08	2019-05-30	Glaxosmithkline Intellectual Property Development Limited	Chemical Compounds
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
SG11202004307UA (en)	2017-11-21	2020-06-29	Axerovision Inc	Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US11759472B2 (en)	2017-11-21	2023-09-19	Cs Pharmaceuticals Limited	Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
JP2023519585A (ja)	2020-03-26	2023-05-11	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	ウイルス感染を予防または治療するカテプシン阻害剤
CN120344544A (zh) *	2023-01-10	2025-07-18	四川科伦博泰生物医药股份有限公司	糖皮质激素受体激动剂及其偶联物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2856828A (en) *	1955-01-24	1958-10-21	Leukart Machine Co Inc J	Impacting machine
US3943124A (en) *	1970-12-17	1976-03-09	Gordon Hanley Phillipps	Chemical compounds
GB1384372A (en)	1971-01-20	1975-02-19	Glaxo Lab Ltd	Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3686978A (en)	1971-04-09	1972-08-29	Fairfied Mfg Co Inc	Plantetary reduction wheel hub
GB1438940A (en) *	1972-07-19	1976-06-09	Glaxo Lab Ltd	17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1514476A (en)	1974-08-30	1978-06-14	Glaxo Lab Ltd	Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
US4093721A (en) *	1974-08-30	1978-06-06	Glaxo Laboratories Limited	Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
GB2137206B (en) *	1980-02-15	1985-04-03	Glaxo Group Ltd	Androstane 17-carbothioc acid derivatives
US4996335A (en)	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
SE449106B (sv) *	1980-07-10	1987-04-06	Otsuka Pharma Co Ltd	Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
WO1989003390A1 (en)	1987-10-13	1989-04-20	Bodor Nicholas S	Soft steroids having anti-inflammatory activity
US5990099A (en)	1988-10-31	1999-11-23	Alcon Laboratories, Inc.	Angiostatic agents and methods and compositions for controlling ocular hypertension
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
NZ251092A (en)	1992-04-02	1996-12-20	Smithkline Beecham Corp	4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
CN1070849C (zh)	1994-06-15	2001-09-12	惠尔康基金会集团公司	酶抑制剂
US6172054B1 (en)	1995-06-15	2001-01-09	Alcon Laboratories, Inc.	Combination therapy for lowering and controlling intraocular pressure
AU1970197A (en)	1996-05-09	1997-11-26	Alcon Laboratories, Inc.	Use of steroid compounds to prevent non-cancerous tissue growth
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
US6245804B1 (en)	1997-05-30	2001-06-12	Schering Aktiengesellschaft	Nonsteroidal gestagens
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
AU9281298A (en)	1997-10-01	1999-04-23	Kyowa Hakko Kogyo Co. Ltd.	Benzodioxole derivatives
JP4219554B2 (ja)	1997-10-01	2009-02-04	協和発酵キリン株式会社	ベンゾフラン誘導体
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en)	1998-03-14	2004-12-31	Altana Pharma Ag	Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
HK1043788A1 (zh)	1999-05-04	2002-09-27	American Home Products Corporation	四環黃體酮受體調節劑化合物及方法
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en)	1999-07-28	2001-07-17	Motorola, Inc.	Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
GB0015876D0 (en) *	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
JP4436041B2 (ja) *	2000-08-05	2010-03-24	グラクソグループリミテッド	抗炎症剤としての６α，９α−ジフルオロ−１７α−［（２−フラニルカルボキシル）オキシ］−１１β−ヒドロキシ−１６α−メチル−３−オキソ−アンドロスト−１，４−ジエン−１７−チオカルボン酸Ｓ−フルオロメチルエステル
JP5089846B2 (ja)	2000-09-29	2012-12-05	グラクソグループリミテッド	炎症性疾患を処置するためのモルホリン−アセトアミド誘導体
WO2002040030A1 (en)	2000-11-16	2002-05-23	Alcon Manufacturing, Ltd.	Combination therapy for lowering and controlling intraocular pressure
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
ATE365720T1 (de)	2001-03-08	2007-07-15	Glaxo Group Ltd	Agonisten von beta-adrenorezeptoren
ATE381537T1 (de)	2001-03-22	2008-01-15	Glaxo Group Ltd	Formanilid-derivative als beta2-adrenorezeptor- agonisten
BR0209271A (pt) *	2001-04-30	2004-06-15	Glaxo Group Ltd	Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
SI1425001T1 (sl)	2001-09-14	2009-04-30	Glaxo Group Ltd Glaxo Welcome	Fenetanolaminski derivati za zdravljenje respiratornih bolezni
GB0125259D0 (en) *	2001-10-20	2001-12-12	Glaxo Group Ltd	Novel compounds
US6653323B2 (en)	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
ES2276038T3 (es)	2002-01-14	2007-06-16	Boehringer Ingelheim Pharmaceuticals Inc.	Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
AU2003202044A1 (en) *	2002-01-15	2003-09-09	Glaxo Group Limited	17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003061651A1 (en)	2002-01-22	2003-07-31	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
JP4324480B2 (ja)	2002-03-26	2009-09-02	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
JP2005521717A (ja)	2002-03-26	2005-07-21	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
US6897224B2 (en)	2002-04-02	2005-05-24	Schering Ag	Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
ATE496620T1 (de)	2002-04-11	2011-02-15	Merck Sharp & Dohme	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE60318193T2 (de)	2002-04-25	2008-12-04	Glaxo Group Ltd., Greenford	Phenethanolaminderivate
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SI1521733T1 (sl)	2002-07-08	2014-10-30	Pfizer Products Inc.	Modulatorji glukokortikoidnega receptorja
JP2006508042A (ja)	2002-07-18	2006-03-09	ブリストル−マイヤーズ　スクイブ　カンパニー	グルココルチコイド受容体の修飾物質および方法
US7442554B2 (en)	2002-07-18	2008-10-28	Bristol-Myers Squibb Company	Compositions and methods involving glucocorticoid receptor site II
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
AU2003259747A1 (en)	2002-08-21	2004-03-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
PL375993A1 (en)	2002-09-16	2005-12-12	Glaxo Group Limited	Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
CA2499150A1 (en)	2002-09-20	2004-04-01	Merck & Co., Inc.	Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
AU2003298094A1 (en)	2002-10-22	2004-05-13	Glaxo Group Limited	Medicinal arylethanolamine compounds
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
EP1556342B1 (en)	2002-10-28	2008-03-26	Glaxo Group Limited	Phenethanolamine derivative for the treatment of respiratory diseases
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds

2003
- 2003-07-11 GB GBGB0316290.6A patent/GB0316290D0/en not_active Ceased
2004
- 2004-07-08 AR ARP040102428A patent/AR045901A1/es unknown
- 2004-07-08 AR ARP040102427A patent/AR045900A1/es unknown
- 2004-07-09 CA CA2531911A patent/CA2531911C/en not_active Expired - Fee Related
- 2004-07-09 PL PL04741020T patent/PL1644397T3/pl unknown
- 2004-07-09 PT PT04741020T patent/PT1644397E/pt unknown
- 2004-07-09 CA CA2531905A patent/CA2531905C/en not_active Expired - Fee Related
- 2004-07-09 PT PT47632260T patent/PT1644398E/pt unknown
- 2004-07-09 RU RU2005141064/04A patent/RU2348645C2/ru active
- 2004-07-09 CN CN2011102290522A patent/CN102372756A/zh active Pending
- 2004-07-09 DK DK04741020.4T patent/DK1644397T3/da active
- 2004-07-09 BR BRPI0412526-6A patent/BRPI0412526A/pt not_active Application Discontinuation
- 2004-07-09 WO PCT/EP2004/007820 patent/WO2005005452A1/en not_active Ceased
- 2004-07-09 WO PCT/EP2004/007819 patent/WO2005005451A1/en not_active Ceased
- 2004-07-09 SI SI200432006T patent/SI1644398T1/sl unknown
- 2004-07-09 MY MYPI20042752A patent/MY137944A/en unknown
- 2004-07-09 EP EP04741020A patent/EP1644397B1/en not_active Expired - Lifetime
- 2004-07-09 US US10/564,299 patent/US7291609B2/en not_active Expired - Lifetime
- 2004-07-09 JP JP2006518181A patent/JP4709752B2/ja not_active Expired - Fee Related
- 2004-07-09 TW TW093120707A patent/TWI338694B/zh not_active IP Right Cessation
- 2004-07-09 AU AU2004255855A patent/AU2004255855B2/en not_active Ceased
- 2004-07-09 EP EP04763226A patent/EP1644398B1/en not_active Expired - Lifetime
- 2004-07-09 RU RU2005141226/04A patent/RU2359973C2/ru active
- 2004-07-09 HR HR20100359T patent/HRP20100359T1/hr unknown
- 2004-07-09 ES ES04763226T patent/ES2400821T3/es not_active Expired - Lifetime
- 2004-07-09 BR BRPI0412527-4A patent/BRPI0412527A/pt not_active Application Discontinuation
- 2004-07-09 CN CN2004800256690A patent/CN1849330B/zh not_active Expired - Fee Related
- 2004-07-09 PL PL04763226T patent/PL1644398T3/pl unknown
- 2004-07-09 MX MXPA06000442A patent/MXPA06000442A/es active IP Right Grant
- 2004-07-09 US US10/564,325 patent/US7288536B2/en not_active Expired - Lifetime
- 2004-07-09 EP EP11151276.0A patent/EP2380898B1/en not_active Expired - Lifetime
- 2004-07-09 KR KR1020067000738A patent/KR101075324B1/ko not_active Expired - Fee Related
- 2004-07-09 DK DK04763226.0T patent/DK1644398T3/da active
- 2004-07-09 TW TW093120698A patent/TWI367888B/zh not_active IP Right Cessation
- 2004-07-09 NZ NZ544577A patent/NZ544577A/en not_active IP Right Cessation
- 2004-07-09 ES ES04741020T patent/ES2343685T3/es not_active Expired - Lifetime
- 2004-07-09 HR HRP20130056TT patent/HRP20130056T1/hr unknown
- 2004-07-09 AU AU2004255854A patent/AU2004255854B2/en not_active Ceased
- 2004-07-09 CN CN2004800255908A patent/CN1845933B/zh not_active Expired - Fee Related
- 2004-07-09 JP JP2006518180A patent/JP4709751B2/ja not_active Expired - Fee Related
- 2004-07-09 NZ NZ544576A patent/NZ544576A/en not_active IP Right Cessation
- 2004-07-09 KR KR1020067000690A patent/KR101029207B1/ko not_active Expired - Fee Related
- 2004-07-09 MY MYPI20042746A patent/MY140987A/en unknown
- 2004-07-09 SI SI200431471T patent/SI1644397T1/sl unknown
- 2004-07-09 AT AT04741020T patent/ATE467638T1/de active
- 2004-07-09 ES ES11151276T patent/ES2433665T3/es not_active Expired - Lifetime
- 2004-07-09 MX MXPA06000443A patent/MXPA06000443A/es active IP Right Grant
- 2004-07-09 DE DE602004027137T patent/DE602004027137D1/de not_active Expired - Lifetime
2005
- 2005-12-22 IL IL172776A patent/IL172776A/en active IP Right Grant
- 2005-12-22 IS IS8194A patent/IS2776B/is unknown
- 2005-12-22 IL IL172777A patent/IL172777A/en active IP Right Grant
- 2005-12-22 IS IS8193A patent/IS2909B/is unknown
2006
- 2006-01-06 NO NO20060110A patent/NO332041B1/no not_active IP Right Cessation
- 2006-01-06 MA MA28701A patent/MA27897A1/fr unknown
- 2006-01-06 NO NO20060111A patent/NO333263B1/no not_active IP Right Cessation
- 2006-01-06 MA MA28703A patent/MA27899A1/fr unknown
- 2006-01-10 ZA ZA200600223A patent/ZA200600223B/en unknown
- 2006-01-10 ZA ZA200600226A patent/ZA200600226B/en unknown
2007
- 2007-09-28 US US11/863,390 patent/US7638508B2/en not_active Expired - Lifetime
- 2007-09-28 US US11/863,419 patent/US20080021231A1/en not_active Abandoned
- 2007-09-28 US US11/863,439 patent/US7524970B2/en not_active Expired - Lifetime
2009
- 2009-04-03 RU RU2009112207/04A patent/RU2009112207A/ru not_active Application Discontinuation
2010
- 2010-03-01 US US12/714,961 patent/US20100152148A1/en not_active Abandoned
- 2010-06-30 CY CY20101100601T patent/CY1110149T1/el unknown
- 2010-12-23 IL IL210209A patent/IL210209A0/en unknown
2011
- 2011-01-07 JP JP2011001699A patent/JP2011093929A/ja active Pending
2013
- 2013-03-19 CY CY20131100230T patent/CY1113836T1/el unknown
2014
- 2014-10-28 IS IS050094A patent/IS2928B/is unknown

Also Published As

Publication number	Publication date
IL210209A0 (en)	2011-03-31
US20070043007A1 (en)	2007-02-22
SI1644397T1 (sl)	2010-09-30
MXPA06000442A (es)	2006-04-07
US7291609B2 (en)	2007-11-06
MY140987A (en)	2010-02-12
TW200524954A (en)	2005-08-01
CN102372756A (zh)	2012-03-14
US20060247219A1 (en)	2006-11-02
RU2009112207A (ru)	2010-10-10
CA2531911A1 (en)	2005-01-20
SI1644398T1 (sl)	2013-04-30
ES2343685T3 (es)	2010-08-06
NO333263B1 (no)	2013-04-22
GB0316290D0 (en)	2003-08-13
US20100152148A1 (en)	2010-06-17
US7288536B2 (en)	2007-10-30
PL1644397T3 (pl)	2010-10-29
IS2928B (is)	2015-09-15
PT1644398E (pt)	2013-03-05
HRP20130056T1 (hr)	2013-02-28
NZ544576A (en)	2009-06-26
EP2380898A1 (en)	2011-10-26
PT1644397E (pt)	2010-07-01
JP2009513533A (ja)	2009-04-02
EP2380898B1 (en)	2013-08-28
RU2359973C2 (ru)	2009-06-27
JP2009514781A (ja)	2009-04-09
NO20060110L (no)	2006-02-09
CA2531905A1 (en)	2005-01-20
KR101075324B1 (ko)	2011-10-19
ZA200600226B (en)	2007-04-25
IL172776A (en)	2015-05-31
CA2531911C (en)	2011-11-01
EP1644397A1 (en)	2006-04-12
RU2005141064A (ru)	2006-08-10
DK1644398T3 (da)	2013-02-04
US20080070880A1 (en)	2008-03-20
IS8194A (is)	2005-12-22
KR101029207B1 (ko)	2011-04-12
HK1089186A1 (en)	2006-11-24
CN1849330A (zh)	2006-10-18
US20080015360A1 (en)	2008-01-17
EP1644398A1 (en)	2006-04-12
JP2011093929A (ja)	2011-05-12
MA27899A1 (fr)	2006-05-02
RU2005141226A (ru)	2006-08-27
MXPA06000443A (es)	2006-04-07
NO332041B1 (no)	2012-06-11
CY1110149T1 (el)	2015-01-14
ATE467638T1 (de)	2010-05-15
DK1644397T3 (da)	2010-08-23
US20080021231A1 (en)	2008-01-24
AU2004255855A1 (en)	2005-01-20
CA2531905C (en)	2012-05-08
AR045900A1 (es)	2005-11-16
IS050094A (is)	2014-10-28
CY1113836T1 (el)	2016-07-27
ZA200600223B (en)	2007-04-25
IS8193A (is)	2005-12-22
IS2776B (is)	2012-03-15
WO2005005451A1 (en)	2005-01-20
PL1644398T3 (pl)	2013-05-31
TWI367888B (en)	2012-07-11
NZ544577A (en)	2009-07-31
CN1845933B (zh)	2011-10-05
NO20060111L (no)	2006-01-24
AU2004255854B2 (en)	2009-10-22
WO2005005452A1 (en)	2005-01-20
MA27897A1 (fr)	2006-05-02
IL172777A0 (en)	2006-04-10
JP4709751B2 (ja)	2011-06-22
TW200524953A (en)	2005-08-01
US7524970B2 (en)	2009-04-28
JP4709752B2 (ja)	2011-06-22
CN1849330B (zh)	2011-05-25
KR20060052801A (ko)	2006-05-19
IL172777A (en)	2012-05-31
BRPI0412526A (pt)	2006-09-19
KR20060052807A (ko)	2006-05-19
ES2400821T3 (es)	2013-04-12
AU2004255854A1 (en)	2005-01-20
AU2004255855B2 (en)	2009-07-30
EP1644398B1 (en)	2013-01-09
MY137944A (en)	2009-04-30
IL172776A0 (en)	2006-04-10
RU2348645C2 (ru)	2009-03-10
AR045901A1 (es)	2005-11-16
CN1845933A (zh)	2006-10-11
HK1089185A1 (en)	2006-11-24
TWI338694B (en)	2011-03-11
ES2433665T3 (es)	2013-12-12
US7638508B2 (en)	2009-12-29
HRP20100359T1 (hr)	2010-07-31
DE602004027137D1 (de)	2010-06-24
BRPI0412527A (pt)	2006-09-19
EP1644397B1 (en)	2010-05-12

Publication	Publication Date	Title
IS8193A (is)	2005-12-22	Sértækt sykurstera efnasamband sem hefur bólgueyðandi virkni
IS8941A (is)	2010-12-29	Efnasambönd með bólgueyðandi virkni
IS7469A (is)	2004-09-24	4-anilínókínasólínafleiður sem andfjölgunarefni
DK1362582T3 (da)	2008-04-21	Overtrukket fast doseringsform
DE60304290D1 (de)	2006-05-18	Anti-Siphonvorrichtung
IS7644A (is)	2005-01-12	Heteró bíarýl afleiður sem fylkis metallóprótínasa hindrar
IS2577B (is)	2010-02-15	Trópan afleiður sem CCR5 stillar
DE50310866D1 (de)	2009-01-15	Flanschverbindung
ATE414705T1 (de)	2008-12-15	Entzündungshemmende di- und trifluortriazolopyridin-verbindungen
EP1631259A4 (en)	2006-08-02	OTOLOGICAL NANOTECHNOLOGY
ITMI20020148A1 (it)	2003-07-29	Nuovi corticosteroidi
IS7793A (is)	2005-04-11	Nýtt efnasamband
IS7827A (is)	2005-04-27	Ný efnasambönd
AU2003282510A8 (en)	2004-05-04	Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
IL175857A0 (en)	2008-02-09	Anti-inflammatory agents
DE60324196D1 (de)	2008-11-27	Narcistatin-prodrugs
SE0401032D0 (sv)	2004-04-22	A new acute glucocorticoid therapy
GB0327775D0 (en)	2003-12-31	Anti-inflammatory agents
GB0318014D0 (en)	2003-09-03	Anti-inflammatory agent
GB0427136D0 (en)	2005-01-12	Anti-inflammatory compounds
SE0202007D0 (sv)	2002-06-27	New compound
GB0417436D0 (en)	2004-09-08	Anti-inflammatory agents
GB0417734D0 (en)	2004-09-08	Anti-Inflammatory agents
GB0328752D0 (en)	2004-01-14	Anti-inflammatory compounds
GB0311576D0 (en)	2003-06-25	Anti-inflammatory agents